CJC-1295 NO DAC Peptide: The Complete Guide - Uses, Mechanism, Dosing, Safety & Research

Quick Facts

What CJC-1295 NO DAC Does & How It Works

What It Does , Functional Outcomes

• Stimulates the pituitary gland to release growth hormone in short, natural-style pulses rather than a flat, sustained elevation
• Drives downstream IGF-1 production, which supports protein synthesis, lean mass maintenance, and tissue repair
• Promotes mobilization of stored fat as an energy source, with a preference for visceral adipose tissue in animal models
• Supports faster recovery from training and physical stress, with improvements in sleep architecture, particularly slow-wave sleep depth
• Preserves receptor sensitivity through pulsatile rather than continuous stimulation, reducing the theoretical risk of desensitization with long-term use
• Contributes to bone formation and may counteract glucocorticoid-induced bone suppression in research models

How It Works , Mechanism of Action

GHRH Receptor Activation and Pulsatile GH Secretion (Evidence: Animal)

CJC-1295 NO DAC binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary - the same receptor that the body's own GHRH uses. This binding triggers a G-protein coupled receptor signaling cascade. Adenylyl cyclase activates, cyclic adenosine monophosphate (cAMP) production increases, and protein kinase A (PKA) then phosphorylates targets that drive GH gene transcription and secretion from stored vesicles. The four amino acid substitutions versus native GHRH (1-29) improve resistance to dipeptidyl peptidase-IV (DPP-IV) enzymatic cleavage, extending the compound's functional window without requiring albumin binding. The result is GH release in pulses, not a sustained elevation, that closely mimics the body's natural secretory pattern.

IGF-1 Pathway Stimulation (Evidence: Animal / Human - extrapolated from DAC trials)

GH released following CJC-1295 NO DAC administration travels to the liver and activates JAK-STAT signaling, which drives insulin-like growth factor 1 (IGF-1) production. IGF-1 then acts on peripheral tissues - muscle, bone, connective tissue - to promote protein synthesis, satellite cell activation, collagen production, and osteoblast activity. In preclinical models, IGF-1 elevations persist for 24-48 hours following a single dose, significantly outlasting the peptide's plasma half-life of 30 minutes to 2 hours. In the human trial using the WITH DAC version, IGF-1 increased 1.5- to 3-fold following single administration.

GH-Mediated Lipolysis (Evidence: Animal)

Growth hormone activates hormone-sensitive lipase in adipose tissue, promoting breakdown of stored triglycerides into free fatty acids available for energy. Animal body composition research has consistently shown preferential reduction of visceral adipose tissue - the metabolically active fat around organs - over subcutaneous fat. Metabolic effects including improvements in glucose homeostasis and lipid profiles have been documented in animal models of insulin resistance, mediated through both direct GH actions and downstream IGF-1 signaling.

Circadian GH Pulse Amplification (Evidence: Animal / Mechanistic)

The body's largest natural GH pulses occur during slow-wave sleep phases. CJC-1295 NO DAC administered pre-sleep amplifies these nocturnal pulses rather than creating an artificial independent GH release event. This timing-aligned approach produces enhanced slow-wave sleep depth and improved recovery markers in animal models, and it is the mechanistic basis for the pre-sleep injection timing documented consistently in practitioner and community protocols.

Receptor Sensitivity Preservation (Evidence: Mechanistic / Animal)

Because CJC-1295 NO DAC produces intermittent rather than continuous GHRH receptor stimulation, normal somatostatin feedback mechanisms remain operative throughout. Somatostatin is the body's natural brake on GH secretion - it downregulates GH output between pulses. Pulsatile stimulation preserves this feedback loop, theoretically reducing the receptor desensitization risk that continuous stimulation carries. This is the primary mechanistic argument for the NO DAC design philosophy over the WITH DAC version in protocols where long-term receptor sensitivity is a priority.

CJC-1295 NO DAC Molecular Profile

Structure reference: View on PubChem CID 91976842 - Publishing team: retrieve 2D structure image from this link.

CJC-1295 NO DAC Uses & Benefits

Body Composition , Lean Mass and Fat Loss

CJC-1295 NO DAC is most frequently researched and documented for body composition goals: increasing lean mass while reducing fat, particularly visceral fat. The mechanism is straightforward - stimulated GH pulses drive IGF-1 production that supports protein synthesis and satellite cell activation, while GH-mediated lipolysis preferentially mobilizes visceral adipose tissue. Animal body composition studies confirm reduced fat percentage and improved muscle-to-fat ratio, with effects more pronounced in aging models where endogenous GH secretion has declined. Evidence from human populations is extrapolated from the WITH DAC version trials rather than directly established for the NO DAC compound. (Evidence: Animal - Alba et al., 2006)

Recovery and Muscle Repair

Recovery from training and physical injury is a primary focus in both practitioner protocols and community documentation. The IGF-1 elevation following GH stimulation drives satellite cell activation - the cellular process responsible for muscle fiber repair and regeneration - and enhances collagen synthesis for connective tissue repair. Reduced nitrogen loss in catabolic states has been documented in combination protocols with Ipamorelin in preclinical models, suggesting improved nitrogen balance relevant to muscle preservation following intense training. Early onset of sleep quality improvements with pre-sleep dosing often makes this one of the first effects users document. (Evidence: Animal - preclinical model data)

Growth Hormone Deficiency Research

The most direct mechanistic evidence for CJC-1295 NO DAC comes from growth hormone-deficient animal models, particularly the GHRHKO mouse study by Alba and colleagues (2006), where daily administration normalized body weight, organ development, and GH pulse amplitude from near-zero baseline. Research into adult GH decline - whether from aging or pathological GHD - represents one of the compound's more studied preclinical applications. The ability to restore GH pulsatility rather than simply elevate basal GH is relevant because physiological GH function is fundamentally pulsatile, and disrupting that pattern through sustained administration has its own theoretical consequences. (Evidence: Animal - Alba et al., 2006)

Bone Health and Connective Tissue

Bone formation research represents a meaningful application area supported by animal studies. GHRH analog treatment has been shown in preclinical models to preserve bone mineral content and improve trabecular bone parameters in animals undergoing glucocorticoid therapy - a significant concern for anyone using long-term corticosteroid medications. Longitudinal bone growth rate increases from 42 to 52 micrometers per day were documented in relevant animal models examining GH secretagogue effects. Collagen synthesis enhancement relevant to ligament and tendon health is a downstream IGF-1 effect documented in GH secretagogue research. (Evidence: Animal)

Metabolic Health

Metabolic applications including improved glucose homeostasis, insulin sensitivity, and lipid profile optimization have been documented in diabetic and insulin-resistant animal models. GH's acute effects on insulin sensitivity are complex - GH can transiently reduce insulin sensitivity while IGF-1 improves it - making this an area requiring careful consideration rather than straightforward application. Lipid profile improvements including triglyceride reduction and HDL ratio optimization have been observed in animal metabolic studies. (Evidence: Animal)

Where This Guide Comes From

CJC-1295 NO DAC Results & Timelines

Sleep Quality and Recovery

• Week 1-2: Sleep quality improvements are typically the earliest reported effect - specifically increased slow-wave sleep depth, more vivid dreams, and a subjective sense of more restorative sleep. This is mechanistically consistent with CJC-1295 NO DAC's amplification of nocturnal GH pulses.
• Week 2-4: Faster return from training commonly reported. Reduced delayed onset muscle soreness and improved readiness for subsequent sessions are among the most consistently documented early effects in protocol logs.

Body Composition

• Week 1-2: Most users report little visible change. Some experience mild transient water retention in the first week - a normal GH-class effect that typically resolves.
• Week 3-6: Subtle improvements in muscle fullness and early changes in body composition begin to appear. Not dramatic at this stage, but the trajectory becomes apparent.
• Week 6-12: Meaningful body composition changes - visible reduction in visceral fat and improvements in lean mass - are most commonly reported in the eight-to-twelve week range. This is where the compounding effect of sustained IGF-1 elevation, improved sleep, and enhanced recovery becomes apparent. Outcomes are significantly influenced by concurrent training intensity, nutrition, and cycle compliance.

Strength and Performance

• Week 3-6: Incremental strength and output improvements occasionally reported, often attributed to improved recovery capacity rather than direct strength gains.
• Week 8-12: More consistent performance improvements documented, particularly in training contexts where recovery was previously the limiting factor.

How to Administer CJC-1295 NO DAC

Subcutaneous Injection (SubQ)

SubQ injection is the primary and most documented administration route for CJC-1295 NO DAC. Injection into the subcutaneous fat layer - typically the abdomen, upper thigh, or outer arm - allows consistent absorption with a well-characterized onset of peak plasma concentration within 30-60 minutes. This route is preferred in virtually all documented protocols because it is practical for frequent dosing and produces reliable pharmacokinetic behavior in animal models.

Intramuscular Injection (IM)

Intramuscular injection is an alternative route that is occasionally used but less commonly documented than SubQ for CJC-1295 NO DAC. IM injection may produce slightly faster absorption due to the higher vascularity of muscle tissue, but the practical advantage over SubQ for this compound is not established in the literature. Most practitioner and community protocols use SubQ as the default.

Oral

Oral administration is not effective for CJC-1295 NO DAC. It is a 29-amino acid peptide with a molecular weight of 3,367.9 Da - gastric acid and digestive proteases break it down before it can reach systemic circulation in biologically active form. No oral formulation has been documented as effective for this compound. Products marketed as oral CJC-1295 supplements do not have a plausible delivery mechanism for the intact peptide to function.

CJC-1295 NO DAC Dosage & Cycle Length

CJC-1295 NO DAC has a well-documented broad dosing range in the literature and across practitioner protocols - though because the primary human clinical data used the WITH DAC version, translating those numbers directly to NO DAC practice requires some care. What follows reflects the range that appears consistently across preclinical research, practitioner documentation, and community protocol data.

Overall dosing range: 100-200 mcg per injection - range varies by goal and individual

How the goal shifts where you land:

• Low end of range (100 mcg): commonly associated with sleep quality, recovery, and general wellness protocols; also used as a starting point for those new to GH secretagogues or sensitive to GH-class side effects
• Mid range (100-150 mcg): commonly associated with body composition goals and sustained recovery support; the most frequently documented range in practitioner-supervised protocols
• High end of range (200 mcg): sometimes used for more aggressive body composition or recovery goals, or in combination protocols with Ipamorelin where the synergistic effect allows each compound to work at its lower effective dose (evidence grade: Preliminary - preclinical and practitioner-documented)

Frequency: Once or twice daily, timed to coincide with natural GH release windows. The most documented timing is pre-sleep administration to amplify the nocturnal GH pulse. Some protocols add a second injection in the morning on waking. Injections are typically administered at least 30-60 minutes away from meals and carbohydrate intake, as elevated blood glucose and insulin can blunt GH release.

Cycle length: Typically 8-12 weeks, followed by a break of 4 weeks to allow receptor sensitivity to reset. Some practitioner-supervised protocols run longer with periodic breaks built in. Continuous uninterrupted use beyond 12 weeks without a break is not standard in documented protocols.

Loading protocols: No formal loading phase is documented for CJC-1295 NO DAC. Some practitioners use a gradual introduction approach - starting at 100 mcg daily for the first one to two weeks before moving to the target dose - to allow tolerance assessment. This is not a formal titration protocol from published research but a cautious practical pattern in community documentation.

When used in combination with Ipamorelin: The most common documented pairing uses both compounds at 100-200 mcg per injection, administered simultaneously once or twice daily. The dual-pathway mechanism - CJC-1295 NO DAC acting on GHRH receptors and Ipamorelin acting on ghrelin/GHS-R1a receptors - produces synergistic GH pulse amplification that can exceed what either compound produces alone.

CJC-1295 NO DAC Vial Sizes, Costs & Quality

Common vial sizes: 2 mg and 5 mg are the standard vial sizes for CJC-1295 NO DAC in the current market. Some suppliers offer 10 mg vials, though these are less common for this compound.

Typical cost range: $40-$80 per vial for U.S.-manufactured research-grade peptides at current market pricing - varies by supplier, vial size, and purity level. Combination vials containing both CJC-1295 NO DAC and Ipamorelin are available from some suppliers and typically reflect combined vial pricing.

Storage - lyophilized (dry powder):

• Temperature: Freeze at -20 degrees C for long-term storage; refrigeration below 4 degrees C is acceptable for shorter-term storage up to a few weeks
• Shelf life: Approximately 24 months when stored frozen in original packaging
• Light sensitivity: Protect from light; store away from direct light exposure

Storage - reconstituted (in solution):

• Temperature: Requires refrigeration at 2-8 degrees C
• Use window: Typically 14-28 days once reconstituted, depending on bacteriostatic agent used

Normal appearance after reconstitution: CJC-1295 NO DAC dissolves into a clear, colorless solution. Any persistent cloudiness, visible particles, or chunking after thorough mixing indicates a quality issue.

Signs of degradation: Visible particulates that do not dissolve with gentle mixing, significant discoloration (yellow or brown tint), or unusual odor. Degraded peptide should not be used.

Quality Considerations

Peptide quality is not an abstract concern for CJC-1295 NO DAC - it is a compound where synthesis precision actually matters. The four strategic amino acid substitutions that define this peptide require accurate positioning during synthesis; get them wrong and you have a compound with different receptor binding characteristics, different enzyme resistance, and potentially different biological activity than intended. When pricing is significantly below market norms, the cut is almost always in synthesis purity, HPLC verification, or third-party testing. The majority of CJC-1295 NO DAC available online originates from overseas facilities where manufacturing standards, quality controls, and chain of custody are not independently verifiable. U.S.-manufactured research peptides come with third-party purity testing, certificates of analysis, and documented manufacturing processes - you can actually verify what you are getting. That traceability has real value when you are injecting something.

CJC-1295 NO DAC Side Effects & Safety

Side Effect Spectrum

Contraindications

• Active malignancy: GH and IGF-1 are growth promoters; elevated GH and IGF-1 signaling is theoretically contraindicated in the presence of active cancer. This is a precautionary concern based on the GH/IGF-1 axis's known role in cell proliferation rather than a directly demonstrated harm from CJC-1295 NO DAC specifically.
• Acromegaly or known pituitary adenoma: Stimulating additional GH release is contraindicated in conditions already characterized by GH excess.
• Insulin resistance or uncontrolled type 2 diabetes: GH's acute effects on insulin sensitivity and glucose homeostasis require caution; the metabolic context matters.
• Hypothyroidism (untreated): GH secretagogue use in the presence of inadequate thyroid hormone may produce suboptimal results and exacerbate symptoms; insufficient data to characterize the full interaction.
• Hypersensitivity to any component: Standard contraindication for any injectable compound.

Populations Where Caution Is Warranted

• Pregnancy and breastfeeding: Insufficient safety data; use is not recommended without medical supervision
• Pediatric use: Not studied in pediatric populations; not appropriate without medical supervision
• Individuals with pre-existing fluid retention conditions (heart failure, kidney disease, liver disease): GH-class compounds can worsen fluid retention; medical supervision required if use is considered
• Individuals with elevated fasting IGF-1: Adding CJC-1295 NO DAC to an already elevated IGF-1 baseline warrants careful monitoring

Red Flags , Stop Use and Seek Medical Attention If:

• Severe or persistent headache qualitatively different from mild post-injection headache
• Signs of significant hypoglycemia: shaking, cold sweats, confusion, rapid heartbeat
• Joint pain or swelling that is progressive rather than mild and transient
• Significant edema - particularly if affecting the face, hands, and feet simultaneously
• Any signs of allergic reaction: skin rash, throat swelling, difficulty breathing

Drug and Compound Interactions

No formally documented drug-drug interactions have been published specifically for CJC-1295 NO DAC in the peer-reviewed literature. Theoretically, compounds that influence GH secretion, IGF-1 levels, or insulin sensitivity may interact with CJC-1295 NO DAC's effects - including exogenous growth hormone, insulin, and other GH secretagogues. Concurrent use with corticosteroids may blunt GH response, as glucocorticoids are known suppressors of GH secretion. Anyone on medications affecting glucose regulation should be aware that CJC-1295 NO DAC's metabolic effects may alter medication requirements over a protocol.

CJC-1295 NO DAC Research & Studies

Pharmacokinetics & Metabolism

Absorption & Bioavailability

CJC-1295 NO DAC demonstrates high bioavailability via subcutaneous injection, with peak plasma concentrations occurring within 30-60 minutes of administration in rodent models. The four amino acid substitutions versus native GHRH (1-29) - at positions 2, 8, 15, and 27 - provide meaningful resistance to dipeptidyl peptidase-IV (DPP-IV) enzymatic cleavage, extending activity beyond the rapid degradation that limits unmodified GHRH. Bioavailability data specific to human subjects for the NO DAC version is not directly established in published literature.

Half-Life and Distribution

Plasma half-life is 30 minutes to 2 hours, species- and dose-dependent. The compound distributes systemically following absorption and reaches anterior pituitary GHRH receptors within approximately 15-30 minutes in animal models. The deliberate absence of DAC technology preserves this short half-life and the pulsatile stimulation pattern it enables. The half-life figure is established from rodent pharmacokinetic data; direct human half-life measurement for CJC-1295 NO DAC specifically has not been published.

Metabolism & Elimination

The compound is broken down through standard peptidase degradation pathways, with complete elimination typically occurring within 6-8 hours of administration. Renal clearance of peptide fragments is the primary elimination route. No metabolite accumulation has been detected in repeated dosing studies.

Despite a plasma half-life of 30 minutes to 2 hours, GH elevation persists for 4-6 hours post-administration, and IGF-1 elevations in preclinical models persist for 24-48 hours following a single dose. The biological effects significantly outlast the peptide's presence in circulation, suggesting activation of sustained downstream signaling cascades that continue running after the original trigger has cleared.

Mechanistic Research

GHRH Receptor Binding and cAMP-Mediated GH Secretion (Evidence: Animal - Jette et al., 2005)

CJC-1295 and related GHRH analogs activate the GRF receptor on anterior pituitary somatotrophs in rats, as documented by Jette and colleagues in the foundational CJC-1295 receptor characterization study. Receptor activation triggers G-protein coupled signaling: adenylyl cyclase activates, cAMP (cyclic adenosine monophosphate) production rises, and the resulting PKA (protein kinase A) phosphorylation cascade drives GH gene transcription and secretion from stored vesicles. The four amino acid substitutions in CJC-1295 NO DAC enhance receptor binding affinity relative to native GHRH while simultaneously improving DPP-IV resistance.

Pulsatile GH Secretion Preservation Under GHRH Analog Stimulation (Evidence: Human - Ionescu & Frohman, 2006)

Ionescu and Frohman demonstrated in human subjects that pulsatile GH secretion persists even during continuous stimulation by long-acting GHRH analogs - natural pulsatility is not abolished by peptide administration. This finding is foundational for the NO DAC design philosophy: it confirms that the body's own somatostatin feedback mechanisms remain operative during GHRH analog use, and that pulsatile release patterns central to physiological GH function are maintained rather than overridden.

DPP-IV Enzymatic Degradation Resistance , Structural Basis (Evidence: In vitro / Animal - Frohman et al., 1989)

Frohman and colleagues characterized the enzymatic degradation pathways acting on GHRH analogs, specifically documenting DPP-IV and trypsin-like enzymatic cleavage. This foundational work identified exactly why native GHRH has such a short functional window in vivo and established the mechanistic rationale for the amino acid substitution strategy deployed in CJC-1295 NO DAC's design. The substitutions at positions 2, 8, 15, and 27 were specifically chosen to block DPP-IV's preferred cleavage sites while preserving receptor binding geometry.

GH Pulse Amplitude Enhancement , GHRHKO Mouse Model (Evidence: Animal - Alba et al., 2006)

Alba and colleagues studied CJC-1295 in growth hormone-releasing hormone knockout (GHRHKO) mice - animals genetically engineered to lack endogenous GHRH production and therefore severely GH-deficient. Daily administration produced normalization of body weight and length, complete restoration of GH-dependent organ development, somatotroph cell proliferation, and GH pulse amplitude increases of 70-107% over 12-hour experimental periods. Elevated pituitary GH mRNA expression was confirmed, and normalized growth parameters including bone length were observed in previously growth-retarded animals.

Condition-Focused Research

Growth Hormone Deficiency and Pituitary Function {#research-ghd}

The most direct preclinical evidence for CJC-1295 NO DAC's pituitary effects comes from the GHRHKO mouse model (Alba et al., 2006). Animals treated daily showed body weight normalization, restored organ development, increased somatotroph cell proliferation, and GH pulse amplitude increases of 70-107% above baseline over 12-hour experimental periods. This model is a functional analog of severe growth hormone deficiency, making the findings relevant to GHD research contexts - though translation to human GH deficiency management is not yet supported by published clinical trial data specific to the NO DAC compound.

Human Trial Context , Prolonged GH and IGF-1 Elevation {#research-human-trial}

The primary human clinical data relevant to CJC-1295 comes from Teichman and colleagues' 2006 placebo-controlled trial. Important context: this study used CJC-1295 WITH DAC. Key quantified results included 2- to 10-fold increases in plasma GH following a single dose, GH elevations sustained for up to 6 days, and IGF-1 elevations of 1.5- to 3-fold lasting 9-11 days. No serious adverse reactions were reported; doses tested were deemed safe and well-tolerated. The pharmacokinetic parameters are not directly applicable to the NO DAC version due to fundamentally different half-lives, but the downstream mechanistic findings - receptor activation, IGF-1 cascade, safety profile - provide meaningful context for the compound family. (Evidence: Human - Teichman et al., 2006)

Pulsatile GH Secretion in Human Subjects {#research-pulsatility}

The Ionescu and Frohman (2006) study in human subjects directly addressed whether natural pulsatile GH secretion is preserved during GHRH analog administration. The study demonstrated that pulsatile secretion persists even under continuous long-acting stimulation, confirming that endogenous somatostatin feedback mechanisms remain operative. This finding, combined with the NO DAC compound's inherently short half-life, supports the mechanistic argument that CJC-1295 NO DAC produces physiologically patterned rather than pharmacologically distorted GH secretion.

Safety & Tolerability Research

The safety data most applicable to the CJC-1295 compound family from human subjects comes from Teichman et al. (2006), which reported no serious adverse reactions at doses used in healthy adults in the WITH DAC trial. The most commonly reported effects in documented protocols for the NO DAC version align with known GH-class side effects: transient fluid retention, mild headache, and brief post-injection discomfort. The short half-life of the NO DAC version means that if any side effect does occur, its duration is inherently limited - adverse effects that would persist for days with the WITH DAC version typically resolve within hours with the NO DAC compound. No formal long-term safety study specific to CJC-1295 NO DAC in human subjects has been published.

Research Limitations

The most significant limitation for CJC-1295 NO DAC specifically is the absence of a dedicated human clinical trial for this compound. The landmark human data - Teichman et al. (2006) - used the WITH DAC version, and its pharmacokinetic and dosing parameters cannot be directly applied to NO DAC protocols. Most human-applicable evidence is extrapolated from the WITH DAC trials or from the Ionescu and Frohman (2006) pulsatility research, which also used the long-acting version. The animal and preclinical data for the compound is more robust, but the translation gap to human clinical outcomes remains significant. Long-term safety data for either version in human subjects beyond the duration of published trials does not exist in peer-reviewed literature. The combination protocol with Ipamorelin is among the most commonly used in documented practice but has not been evaluated in a formal human clinical trial as a combination regimen.

Is CJC-1295 NO DAC Legal? Regulatory & Sports Status

FDA status: CJC-1295 NO DAC is not approved by the FDA for human use in any indication. It is classified as a research compound. On December 4, 2024, the FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed CJC-1295 compounding nominations for potential inclusion on the 503A Bulks List - which would have allowed licensed compounding pharmacies to prepare it for patients with a valid prescription. The PCAC recommended against inclusion on the 503A Bulks List.

Research Use Only (RUO): In most countries, CJC-1295 NO DAC is classified as a research compound not approved for human use. It is sold under research use designations through peptide suppliers, legally framing it as a research chemical rather than a drug or supplement.

WADA / USADA status: CJC-1295 NO DAC is banned under the WADA Prohibited List in the category of peptide hormones, growth factors, related substances, and mimetics (Section 2). This prohibition applies both in-competition and out-of-competition, as GH secretagogues are subject to year-round testing. Any competitive athlete subject to WADA or USADA rules should treat CJC-1295 NO DAC as prohibited regardless of jurisdiction.

Country-specific notes: Regulatory classification varies by jurisdiction. In Australia, peptides including CJC-1295 NO DAC are classified as Schedule 4 (Prescription Only) substances under the Therapeutic Goods Administration (TGA) framework, requiring a valid prescription for legal use. In the United Kingdom, it does not have specific scheduling status but is subject to general medicines regulation. In Canada, it falls under the Food and Drugs Act. Users in any jurisdiction are responsible for verifying the specific legal status applicable to their location before obtaining or using this compound.

Detection: WADA and USADA maintain testing protocols for GH secretagogues including GHRH analogs. Immunoassay and mass spectrometry-based detection methods have been developed for peptides in this class. Specific detection windows for CJC-1295 NO DAC have not been publicly documented in detail, but the short plasma half-life does not necessarily mean a short detection window - downstream biomarkers such as IGF-1 elevation can extend the detectable signal beyond peptide clearance.

CJC-1295 NO DAC vs. Alternatives

Commonly Paired With , Synergistic Stacks

• CJC-1295 NO DAC + Ipamorelin: The most extensively documented combination in GH secretagogue protocols. CJC-1295 NO DAC activates GHRH receptors while Ipamorelin activates ghrelin/GHS-R1a receptors - two independent pituitary pathways that when triggered simultaneously produce synergistic GH pulse amplification documented in animal models. This is the standard dual-pathway approach in practitioner-supervised GH secretagogue protocols targeting body composition and recovery.
• CJC-1295 NO DAC + BPC-157: Paired occasionally in recovery-focused protocols where tissue repair is the primary goal. CJC-1295 NO DAC contributes systemic GH and IGF-1 elevation supporting muscle and connective tissue repair, while BPC-157 works through local angiogenic and growth factor pathways at specific injury sites. The two compounds operate through entirely different mechanisms with no documented interaction concerns.
• CJC-1295 NO DAC + Ipamorelin + GHRP-2: A three-compound approach documented in more aggressive GH optimization protocols, adding a second ghrelin-pathway secretagogue to the standard dual-pathway stack. Less common than the two-compound pairing. Stacking information is for educational context - individualized stack protocols live inside MPP.

Alternatives , When Another Peptide May Be Considered

CJC-1295 WITH DAC

The most direct structural alternative, differing only in the presence of the Drug Affinity Complex that extends half-life to 5.8-8.1 days. The WITH DAC version suits protocols where weekly dosing convenience is prioritized and sustained IGF-1 elevation is the primary goal - the Teichman et al. (2006) human trial established it can maintain IGF-1 elevation for up to 28 days with repeated dosing. The tradeoff is reduced adjustability, longer side effect duration if any occur, and theoretical higher receptor desensitization risk with chronic use.

Sermorelin

Sermorelin is also a GHRH analog (GHRH 1-29 without the protective substitutions), giving it a mechanistic profile similar to CJC-1295 NO DAC but a shorter effective half-life. It is the only GHRH analog with prior FDA approval history - approved in 1997 for pediatric GH deficiency and later withdrawn for commercial rather than safety reasons. Sermorelin is used in compounding contexts and may be accessible through licensed practitioners for specific indications. Those for whom legal access matters more than potency optimization may consider Sermorelin when it is available through appropriate channels.

Ipamorelin (standalone)

Ipamorelin alone targets the ghrelin/GHS-R1a receptor rather than the GHRH receptor, producing GH secretion through an entirely different pathway. As a standalone compound, it offers selectivity - documented in human pharmacokinetic research as having no significant effect on prolactin, ACTH, or cortisol, making it one of the cleaner GH secretagogues in terms of hormonal specificity. For those seeking GH stimulation with minimal off-target hormonal effects, Ipamorelin alone is the more selective option, though it lacks the GHRH-pathway amplification that CJC-1295 NO DAC contributes to the combination.

GHRP-6 and GHRP-2

Both are ghrelin receptor agonists - the same receptor class as Ipamorelin - with stronger GH secretagogue activity than Ipamorelin but less hormonal selectivity. GHRP-6 notably stimulates hunger and cortisol to a meaningful degree. They function as alternatives to Ipamorelin rather than to CJC-1295 NO DAC when the goal is stronger ghrelin-pathway stimulation alongside a GHRH analog.

Comparison table:

Build Your CJC-1295 NO DAC Protocol

FAQs About CJC-1295 NO DAC Peptide

What is CJC-1295 NO DAC?

CJC-1295 NO DAC is a synthetic 29-amino acid analog of growth hormone-releasing hormone (GHRH), engineered with four amino acid substitutions that improve enzymatic stability while preserving a short plasma half-life of 30 minutes to 2 hours. The "NO DAC" designation distinguishes it from CJC-1295 WITH DAC, which uses Drug Affinity Complex technology to extend its half-life to 5-8 days. CJC-1295 NO DAC stimulates pulsatile growth hormone secretion that mirrors the body's natural rhythms.

What does CJC-1295 NO DAC do?

CJC-1295 NO DAC stimulates the anterior pituitary to release growth hormone in pulses that mimic the body's natural secretory pattern. This GH release drives downstream IGF-1 production, which supports protein synthesis, lean mass preservation, fat mobilization, muscle repair, collagen synthesis, and improvements in slow-wave sleep quality. Its primary research applications are body composition optimization, recovery support, and metabolic health.

How long does CJC-1295 NO DAC take to work?

Sleep quality improvements are typically the earliest reported effect, often appearing within the first one to two weeks of consistent use. Recovery improvements are often reported in the two-to-four week window. Body composition changes develop more gradually, with meaningful changes typically observed at the 8-12 week mark when combined with appropriate training and nutrition. Individual variation is significant and depends on dose, timing, and overall health.

What is the typical dose of CJC-1295 NO DAC?

The most commonly documented dose range across practitioner protocols and preclinical research is 100-200 mcg per injection, administered once or twice daily. Pre-sleep timing is the most frequently documented pattern, aimed at amplifying the natural nocturnal GH pulse. Individual protocols vary based on health status, goals, and what else is being used - build your personalized protocol inside MyPeptidePal.

Is CJC-1295 NO DAC legal?

CJC-1295 NO DAC is classified as a research compound not approved for human use in most jurisdictions, including the United States. The FDA Pharmacy Compounding Advisory Committee recommended against adding it to the 503A Bulks List in December 2024. It is banned year-round under the WADA prohibited list for peptide hormones and growth factors, and specific legal status varies by country.

Can CJC-1295 NO DAC be taken orally?

No. CJC-1295 NO DAC is a 29-amino acid peptide broken down by gastric acid and digestive enzymes before it can reach systemic circulation in biologically active form. At a molecular weight of 3,367.9 Da, it cannot survive the digestive process intact. No oral formulation has been documented as effective for this compound.

What is the difference between CJC-1295 NO DAC and CJC-1295 WITH DAC?

The core difference is the Drug Affinity Complex (DAC) modification - present in one version, absent in the other. The DAC modification causes CJC-1295 to bind to albumin in the bloodstream, extending its half-life from about 30 minutes to 5-8 days. NO DAC produces short, pulsatile GH stimulation requiring daily dosing; WITH DAC creates sustained GH elevation with weekly dosing. NO DAC is considered more physiologically aligned with natural GH secretion patterns.

Why is CJC-1295 NO DAC typically used with Ipamorelin?

CJC-1295 NO DAC and Ipamorelin target two different receptor systems that both stimulate GH release from the pituitary. CJC-1295 NO DAC activates GHRH receptors; Ipamorelin activates ghrelin/GHS-R1a receptors. When both pathways are activated simultaneously, animal model data documents a synergistic GH response exceeding what either compound produces alone, allowing each compound to work effectively within its standard dose range.

Does CJC-1295 NO DAC need to be refrigerated?

In lyophilized (dry powder) form, CJC-1295 NO DAC should be stored frozen at -20 degrees C for long-term preservation, with refrigeration below 4 degrees C acceptable for shorter-term storage. Once reconstituted, it requires refrigeration at 2-8 degrees C and should be used within 14-28 days. A properly stored and reconstituted vial should appear as a clear, colorless solution - visible cloudiness, particulates, or discoloration indicate potential degradation.

Why should the injection be timed around meals?

Growth hormone release is suppressed by elevated blood glucose and insulin. When carbohydrates are consumed, blood sugar rises and insulin increases - both of which blunt GH secretion from the pituitary. To maximize the GH pulse triggered by CJC-1295 NO DAC, injections are typically timed at least 30-60 minutes away from carbohydrate-containing meals. Pre-sleep administration is particularly effective when the last meal was two or more hours prior.

Final Thoughts

CJC-1295 NO DAC occupies a specific and well-defined position in the GH secretagogue research landscape. It is not the most potent compound available, and it is not designed to be. Its defining characteristic is the deliberate preservation of the body's own pulsatile GH release pattern - the choice to keep the half-life short, to work within physiological feedback mechanisms rather than around them, and to enable the kind of adjustable, titratable protocol that sustained GH elevation simply does not allow. The preclinical evidence base is solid and mechanistically coherent: GHRH receptor activation, IGF-1 pathway stimulation, GH-mediated lipolysis, and nocturnal GH pulse amplification are all well-documented in animal models. The human evidence picture is more limited - the landmark human trial data comes from the WITH DAC version, and direct human trial data specific to CJC-1295 NO DAC remains a genuine gap in the published literature.

The most meaningful cautions for anyone researching CJC-1295 NO DAC are these: the evidence base, while promising, has not been validated in large human clinical trials for this specific compound; the theoretical contraindication in the presence of active malignancy is a genuine precautionary consideration given GH and IGF-1's role in cell proliferation; and the regulatory environment is actively evolving, with the FDA's December 2024 compounding committee decision representing a meaningful development. Quality sourcing matters enormously for a peptide where synthesis precision is central to function - the four strategic amino acid substitutions that define this compound require accurate synthesis to produce the intended pharmacological profile.

The broad research picture covered in this guide gives you the foundation. What it cannot give you is a protocol designed around your specific situation, goals, health history, and what else you might be using. That is exactly the problem MyPeptidePal is built to solve - bring what you know here, and the app builds the personalized picture from there.

References

1. Ionescu, M., & Frohman, L.A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism, 91(12), 4792-4797.

2. Teichman, S.L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J.P., & Frohman, L.A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805.

3. Jette, L., Leger, R., Thibaudeau, K., Bherer, P., Pellerin, M., Paradis, V., . . . Bridon, D.P. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 146(7), 3052-3058.

4. Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J.P., Frohman, L.A., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology - Endocrinology and Metabolism, 291(6), E1290-E1294.

5. Frohman, L.A., Downs, T.R., Williams, T.C., Heimer, E.P., Pan, Y.C., & Felix, A.M. (1989). Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. Journal of Clinical Investigation, 83(5), 1533-1540.